19352-22-8

Basic information

• Product Name: 3-CHLORO-N-(3-METHYLPHENYL)PROPANAMIDE
• Synonyms: 3-CHLORO-N-(3-METHYLPHENYL)PROPANAMIDE;PROPANAMIDE, 3-CHLORO-N-(3-METHYLPHENYL)-;3-chloro-N-(3-methylphenyl)propionamide;BBV-021867;Propanamide, N-(3-methylphenyl)-3-chloro-;3-chloro-N-(m-tolyl)propanamide
• CAS NO: 19352-22-8
• Molecular Formula: C₁₀H₁₂ClNO
• Molecular Weight: 197.66
• Mol File: 19352-22-8.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-CHLORO-N-(3-METHYLPHENYL)PROPANAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLORO-N-(3-METHYLPHENYL)PROPANAMIDE(19352-22-8)
• EPA Substance Registry System: 3-CHLORO-N-(3-METHYLPHENYL)PROPANAMIDE(19352-22-8)

Safety Data

• Hazardous Substances Data: 19352-22-8(Hazardous Substances Data)

Upstream product

• 625-36-5 2-chloropropionyl chloride 
• 108-44-1 1-amino-3-methylbenzene 
• 107-94-8 chloropropionic acid 

Downstream Products

• 1088175-03-4 C₁₉H₁₇N₅OS 
• 461407-43-2 3-(3,4-dihydroisoquinolin-2(1H)-yl)-N-(m-tolyl)propanamide 
• 20151-46-6 5-methyl-1,2,3,4-tetrahydroquinolin-2-one 
• 19352-59-1 3,4-dihydro-7-methyl-2(1H)-quinolinone 
• 521915-96-8 2-chloro-3-(chloromethyl)-7-methylquinoline 

Relevant articles and documents

Synthesis, antimicrobial evaluation, DNA gyrase inhibition, and in silico pharmacokinetic studies of novel quinoline derivatives

Herein, we report the synthesis and in vitro antimicrobial evaluation of novel quinoline derivatives as DNA gyrase inhibitors. The preliminary antimicrobial activity was assessed against a panel of pathogenic microbes including Gram-positive bacteria (Streptococcus pneumoniae and Bacillus subtilis), Gram-negative bacteria (Pseudomonas aeruginosa and Escherichia coli), and fungal strains (Aspergillus fumigatus, Syncephalastrum racemosum, Geotrichum candidum, and Candida albicans). Compounds that revealed the best activity were subjected to further biological studies to determine their minimum inhibitory concentrations (MICs) against the selected pathogens as well as their in vitro activity against the E. coli DNA gyrase, to realize whether their antimicrobial action is mediated via inhibition of this enzyme. Four of the new derivatives (14, 17, 20, and 23) demonstrated a relatively potent antimicrobial activity with MIC values in the range of 0.66–5.29 μg/ml. Among them, compound 14 exhibited a particularly potent broad-spectrum antimicrobial activity against most of the tested strains of bacteria and fungi, with MIC values in the range of 0.66–3.98 μg/ml. A subsequent in vitro investigation against the bacterial DNA gyrase target enzyme revealed a significant potent inhibitory activity of quinoline derivative 14, which can be observed from its IC50 value (3.39 μM). Also, a molecular docking study of the most active compounds was carried out to explore the binding affinity of the new ligands toward the active site of DNA gyrase enzyme as a proposed target of their activity. Furthermore, the ADMET profiles of the most highly effective derivatives were analyzed to evaluate their potentials to be developed as good drug candidates.

Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors

Protein arginine methyltransferase 5 (PRMT5) is an epigenetics related enzyme that has been validated as a promising therapeutic target for human cancer. Up to now, two small molecule PRMT5 inhibitors has been put into phase I clinical trial. In the prese

NEUROACTIVE COMPOUNDS AND METHODS OF USING THE SAME

The invention described herein relates generally to neuroactive compounds and compositions for the treatment psychotic disorders, methods for treating psychosis using these neuroactive compounds, and methods for screening for novel neuroactive compounds. Certain aspects are directed to a family of compounds called "finazines." Certain aspects are directed to in vivo screening methods using high-throughput behavioral assays in zebrafish.